Dr. Vaishampayan on the Need to Develop Novel Therapies in mRCC

Ulka N. Vaishampayan, MBBS, FAB, director of the Phase I program at the Rogel Cancer Center and a professor of internal medicine at the University of Michigan, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma (mRCC).

About 50% to 60% of patients with mRCC do not derive a response to immunotherapy or are considered refractory to immunotherapy, Vaishampayan says.

Although these patients may be salvaged with VEGF TKIs, the majority of patients are not being cured of their disease, explains Vaishampayan.

As such, developing novel drugs and targets is critically important to continue moving the field of advanced RCC forward, concludes Vaishampayan.